Home » Stocks » CVSI

CV Sciences, Inc. (CVSI)

Stock Price: $0.5910 USD 0.0310 (5.54%)
Updated Mar 8, 2021 10:14 AM EST - Market open
Market Cap 61.58M
Revenue (ttm) 28.56M
Net Income (ttm) -19.68M
Shares Out 106.76M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE 15.63
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $0.5910
Previous Close $0.5600
Change ($) 0.0310
Change (%) 5.54%
Day's Open 0.5650
Day's Range 0.5611 - 0.6000
Day's Volume 56,353
52-Week Range 0.25 - 1.27

News

Hide News
  • All
  • Videos
  • Press Releases
Zacks Investment Research - 12 hours ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 1 month ago

While cannabis legalization may not be a slam-dunk, that hasn't stopped investors from sending marijuana penny stocks to higher highs. The post 4 Marijuana Penny Stocks Winning Under Democrati...

Other stocks mentioned: ALEAF, HRVSF, MRMD
GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD...

Seeking Alpha - 4 months ago

CV Sciences Inc's (CVSI) CEO Joe Dowling on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 4 months ago

Full line of soothing hemp extracts formulated exclusively for dogs and cats Full line of soothing hemp extracts formulated exclusively for dogs and cats

Zacks Investment Research - 4 months ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD...

GlobeNewsWire - 5 months ago

PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and science PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through n...

GlobeNewsWire - 5 months ago

CV™ Defense now available on CV Sciences website and launching on Amazon.com next week CV™ Defense now available on CV Sciences website and launching on Amazon.com next week

GlobeNewsWire - 6 months ago

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) prod...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) produ...

Seeking Alpha - 7 months ago

CV Sciences' (CVSI) CEO Joseph Dowling on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

THC-free Happy Lane™ expands CV Sciences’ sales channels and consumer access to safe and effective CBD THC-free Happy Lane™ expands CV Sciences’ sales channels and consumer access to safe and ...

GlobeNewsWire - 7 months ago

Clinically researched wide spectrum proprietary plant-based formula supports immune system and respiratory health Clinically researched wide spectrum proprietary plant-based formula supports i...

Zacks Investment Research - 7 months ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol ...

Seeking Alpha - 10 months ago

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

CV Sciences Inc (CVSI) delivered earnings and revenue surprises of -66.67% and 37.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 11 months ago

CV Sciences, Inc. (CVSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 11 months ago

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -250.00% and -18.91%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 1 year ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

CV Sciences Is Worth Another Look

Seeking Alpha - 1 year ago

Debra Borchardt, CEO, Co-founder and Editor-in-Chief of cannabis financial news site Green Market Report, joins us for our 50th episode to discuss the state of the cannabis market.

Other stocks mentioned: ACB, ACRGF, APHA, CGC, CRLBF, CWBHF, GTBIF, MJ, PLNHF, POTX, TCNNF, TOKE, YOLO
Zacks Investment Research - 1 year ago

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -300.00% and -32.29%, respectively, for the quarter ended September 2019.

Seeking Alpha - 1 year ago

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

However, one monstrous hurdle remains.

Seeking Alpha - 1 year ago

Shares of CV Sciences have tumbled recently due to broad concerns about the marijuana industry and greater competition.

The Motley Fool - 1 year ago

A move from the over-the-counter exchange to a major U.S. exchange may be coming for this trio of pot stocks.

Other stocks mentioned: CWBHF, MEDIF
The Motley Fool - 1 year ago

Each and every one of these marijuana stocks has a lower forward P/E ratio than the S&P 500, but is growing substantially faster.

Other stocks mentioned: MEDIF, PLNHF, SPRWF, VGWCF
The Motley Fool - 1 year ago

But do low volatility metrics translate to high confidence for these stocks' future prospects?

Other stocks mentioned: SMG, TRSSF
Seeking Alpha - 1 year ago

CV Sciences is profitable, sports a healthy gross margin, and generates positive free cash flow.

Seeking Alpha - 1 year ago

CV Sciences has a much lower valuation than its closest rival, Charlotte's Web.

Other stocks mentioned: CWBHF
The Motley Fool - 1 year ago

Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.

Other stocks mentioned: CURLF, GWPH
The Motley Fool - 1 year ago

Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?

Other stocks mentioned: CWBHF
The Motley Fool - 1 year ago

These cannabis stocks all offer at least 36% upside.

Other stocks mentioned: CRLBF, CRON
The Motley Fool - 1 year ago

Piper Jaffray likes several U.S. cannabis stocks and one Canadian pot stock better than Aurora.

Other stocks mentioned: CRLBF, CRON, CWBHF, GTBIF
The Motley Fool - 1 year ago

Here's how companies from three different corners of the industry squeezed out a profit in the second quarter.

Other stocks mentioned: IIPR, KR
The Motley Fool - 1 year ago

CBD product sales continued to soar in the second quarter, but not as much as analysts expected.

Seeking Alpha - 1 year ago

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and -3.44%, respectively, for the quarter ended June 2019.

The Motley Fool - 1 year ago

Two Canadian growers and a CBD stock are on this month's avoid list.

Other stocks mentioned: CGC, CTST
Zacks Investment Research - 1 year ago

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

CBD revenue is soaring but there remains doubt that it will transition to sustained long-term growth.

Other stocks mentioned: CWBHF, ELLXF
Seeking Alpha - 1 year ago

CV Sciences is attractively valued relative to its peers in the CBD and cannabis space.

The Motley Fool - 1 year ago

Despite supply and tax problems, some cannabis stocks are expected to make money this year.

Other stocks mentioned: CNPOF, CRLBF, CRON, CWBHF, IIPR, MEDIF, OGI, PLNHF, TCNNF
Seeking Alpha - 1 year ago

The CBD market is extremely hot right now.

The Motley Fool - 1 year ago

Which stock wins in a battle between an up-and-coming biotech and a hemp CBD leader?

Other stocks mentioned: ICPT

About CVSI

CV Sciences operates as a life science company. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets hemp-based cannabidiol (CBD) products under the name of PlusCBD in a range of market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchand... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Joseph D. Dowling
Employees
118
Stock Exchange
OTCMKTS
Ticker Symbol
CVSI
Full Company Profile

Analyst Forecasts

The average 12-month stock price forecast for CV Sciences is 0.92, which is an increase of 55.67% from the latest price.

Price Target
$0.92
(55.67% upside)